share_log

Chimerix | 10-Q: Q3 2024 Earnings Report

Chimerix | 10-Q: Q3 2024 Earnings Report

Chimerix | 10-Q:2024財年三季報
美股SEC公告 ·  2024/11/07 12:33

牛牛AI助理已提取核心訊息

Chimerix reported Q3 2024 revenues of $26,000 and a net loss of $22.9 million ($0.26 per share), compared to revenues of $11,000 and a net loss of $24.0 million ($0.27 per share) in Q3 2023. Research and development expenses increased to $19.6 million from $17.4 million YoY, primarily due to costs related to the Phase 3 ACTION study of dordaviprone and manufacturing expenses.The company continues to advance its Phase 3 ACTION trial evaluating dordaviprone for H3 K27M-mutant diffuse glioma, with over 145 sites now enrolling patients across 15 countries. A recent Independent Data Monitoring Committee safety review recommended the study continue as planned. Management expects interim overall survival data to be available in Q3 2025.As of September 30, 2024, Chimerix maintained a strong financial position with $152.4 million in capital available to fund operations. The company is also pursuing potential approval pathways in Australia, having received Provisional Determination approval in August 2024 and Orphan Drug Designation in September 2024. The company continues development of second-generation compound ONC206, with dose escalation studies expected to complete in 2024.
Chimerix reported Q3 2024 revenues of $26,000 and a net loss of $22.9 million ($0.26 per share), compared to revenues of $11,000 and a net loss of $24.0 million ($0.27 per share) in Q3 2023. Research and development expenses increased to $19.6 million from $17.4 million YoY, primarily due to costs related to the Phase 3 ACTION study of dordaviprone and manufacturing expenses.The company continues to advance its Phase 3 ACTION trial evaluating dordaviprone for H3 K27M-mutant diffuse glioma, with over 145 sites now enrolling patients across 15 countries. A recent Independent Data Monitoring Committee safety review recommended the study continue as planned. Management expects interim overall survival data to be available in Q3 2025.As of September 30, 2024, Chimerix maintained a strong financial position with $152.4 million in capital available to fund operations. The company is also pursuing potential approval pathways in Australia, having received Provisional Determination approval in August 2024 and Orphan Drug Designation in September 2024. The company continues development of second-generation compound ONC206, with dose escalation studies expected to complete in 2024.
Chimerix公佈2024年第三季度收入爲26000美元,淨虧損爲2290萬 ($0.26每股),相比之下,2023年第三季度收入爲11000美元,淨虧損爲2400萬 ($0.27每股)。研發支出同比增加至1960萬,去年爲1740萬,主要是由於與dordaviprone的第三階段ACTION研究及製造業費用相關。該公司繼續推進評估dordaviprone用於H3 K2700萬.mutant瀰漫性膠質瘤的第三階段ACTION試驗,現已有超過145個地點在15個國家招募患者。最近,獨立數據監測委員會的安全審查建議繼續按計劃進行該研究。管理層預計在2025年第三季度將提供中期總體生存數據。截至2...展開全部
Chimerix公佈2024年第三季度收入爲26000美元,淨虧損爲2290萬 ($0.26每股),相比之下,2023年第三季度收入爲11000美元,淨虧損爲2400萬 ($0.27每股)。研發支出同比增加至1960萬,去年爲1740萬,主要是由於與dordaviprone的第三階段ACTION研究及製造業費用相關。該公司繼續推進評估dordaviprone用於H3 K2700萬.mutant瀰漫性膠質瘤的第三階段ACTION試驗,現已有超過145個地點在15個國家招募患者。最近,獨立數據監測委員會的安全審查建議繼續按計劃進行該研究。管理層預計在2025年第三季度將提供中期總體生存數據。截至2024年9月30日,Chimerix保持強勁的財務狀況,擁有15240萬的資金可用於運營。該公司還在澳洲尋求潛在的批准途徑,於2024年8月獲得暫時決定批准,並於2024年9月獲得孤兒藥認定。該公司繼續開發第二代Compound ONC206,預計在2024年完成劑量遞增研究。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 218

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。